Therapnea Labs

Therapnea Labs is an experienced MedTech company with a novel, patented technology to treat “the silent killer” –Obstructive Sleep Apnea (OSA). Therapnea is a stent applied inside the patient's mouth from a dental plate that provides mechanical support for the upper airways to prevent airway collapse. The stent is inserted after the patient is asleep and apnea has started. Therapnea relies on a method to circumvent the gag reflex that, until now, prevented this approach. In a clinical study, Therapnea was validated as being able to circumvent nausea and the gag reflex in 100% of patients and prevent apnea events after the stent was inserted. The company's proof-of-concept clinical study has shown promising results. The company is also developing a device to prevent snoring, based on the same technology.

Therapnea Labs has raised $56K in total funding across 1 rounds. The company is currently at the Pre-Funding stage.

Therapnea Labs was founded in 2013 by Avi Lior (Co-founder & CEO), Noam Hadas (Director & CTO).

Therapnea Labs operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Sensing. Target customers: Healthcare & Life Sciences, Healthcare, Patients.

Therapnea Labs is based in Dudu Dotan Street 3, Netanya, Israel, Center District.